87304-15-2

Basic information

• Product Name: (2S)-2-[[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid
• Synonyms: (2S)-2-[[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid
• CAS NO: 87304-15-2
• Molecular Weight: 408.495
• Mol File: 87304-15-2.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: (2S)-2-[[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-2-[[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid(87304-15-2)
• EPA Substance Registry System: (2S)-2-[[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid(87304-15-2)

Safety Data

• Hazardous Substances Data: 87304-15-2(Hazardous Substances Data)

Usage

Description

(2S)-2-[[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid is a complex organic compound belonging to the peptide class. It is a derivative of the amino acid leucine, featuring multiple functional groups such as amino acids, hydroxyl, and phenyl groups. (2S)-2-[[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid is characterized by its stereochemistry, with the (2S) and (2S,3R) notations indicating the specific spatial arrangement of its atoms.

Uses

Used in Biochemistry and Pharmacology Research:
(2S)-2-[[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid is utilized as a reference standard in biochemical and pharmacological research. Its well-defined structure and functional groups make it a valuable tool for understanding the interactions between peptides and biological systems.
Used in Synthesis of Peptides and Pharmaceuticals:
(2S)-2-[[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid serves as a building block for the synthesis of peptides and pharmaceuticals. Its unique structure allows it to be incorporated into larger molecules with specific biological activities, potentially leading to the development of new drugs and therapeutic agents.
Used in Therapeutic Applications:
Due to its interactions with biological systems and enzymes, (2S)-2-[[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid may have potential therapeutic applications. Its complex structure and functional groups could contribute to its efficacy in treating various diseases or conditions, although further research is needed to explore these possibilities.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 77119-86-9 methyl ((2S,3R)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-4-phenylbutanoyl)-L-leucinate 
• 59554-14-2 (2S,3R)-3-amino-2-hydroxy-4-phenylbutanoic acid 
• 58970-76-6 bestatin 
• 246506-78-5 2-(3-tert-butoxycarbonylamino-2-oxo-4-phenylbutyrylamino)-4-methylpentanoic acid benzyl ester 
• 18942-49-9 Boc-D-Phe-OH 
• 246506-75-2 [1-benzyl-3-cyano-2-oxo-3-(triphenyl-λ⁵-phosphanylidene)-propyl]-carbamic acid tert-butyl ester 
• 172025-60-4 (2S,3R)-3-Azido-2-hydroxy-4-phenyl-butyric acid methyl ester 
• 612096-23-8 (2R,3S)-3-Bromo-2-hydroxy-4-phenyl-butyric acid methyl ester 
• 182699-39-4 (2S,3R)-methyl-2,3-epoxy-4-phenylbutanoic acid 
• 81926-51-4 N-(tert-butyloxycarbonyl)-(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoic acid methyl ester 
• 62023-65-8 (2S,3R)-3-[(tert-butoxycarbonyl) amino]-2-hydroxy-4-phenyl-butanoic acid 
• 869115-78-6 (2S,3R)-2-Acetoxy-3-tert-butoxycarbonylamino-4-phenyl-butyric acid 
• 869115-77-5 (2S,3R)-2-Acetoxy-3-amino-4-phenyl-butyric acid 

Downstream Products

• 246506-80-9 1-{1-[2-(3-tert-butoxycarbonylamino-2-hydroxy-4-phenylbutyrylamino)-4-methyl-pentanoyl]pyrrolidine-2-carbonyl}-pyrrolidine-2-carboxylic acid benzyl ester 
• 1041865-45-5 (S)-2-[1-(dimethylamino)naphthalene-5-sulfonamido]ethyl 2-[(2S,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanamido]-4-methylpentanoate 
• 1312302-10-5 tert-butyl (2R,3S)-3-hydroxy-4-[(S)-4-methyl-1-(methylamino)-1-oxopentan-2-ylamino]-4-oxo-1-phenylbutan-2-ylcarbamate 

Relevant articles and documents

Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy

In our previous study, we discovered a ubenimex-fluorouracil (5FU) conjugates BC-02, which displays significant in vivo anti-tumor activity, however, the instability of BC-02 in plasma limits its further development as a drug candidate. Herein, we designe

TUBULIN BINDING AGENTS

The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity). The compounds are based on the combretastatin A-4 skeletal structure having a tubulin-binding pharmacophore comprising two fused rings (A and B rings) in which the B ring is substituted with (a) an aromatic ring structure (C ring) and (b) a second substituent/functional group that comes off the B ring. The aromatic ring structure is typically a six membered ring phenolic or aniline structure, or may also be a fused ring structure such as a substituted or unsubstituted naphthalene. The second substituent on the B ring may for example be a substituent which has been found to provide enhanced tubulin binding activity (for example a carbonyl group), or may be a substituent that facilitates functionalisation of the B ring (for example an hydroxyl or amine group), or it may be a binding agent for a target that is preferentially expressed on vasculature undergoing angiogenesis, and not expressed on quiescent vasculature.

Development of target protein-selective degradation inducer for protein knockdown

Our previous technique for inducing selective degradation of target proteins with ester-type SNIPER (Specific and Nongenetic Inhibitor-of-apoptosis- proteins (IAPs)-dependent Protein ERaser) degrades both the target proteins and IAPs. Here, we designed a